

**Vancouver Prostate Centre
Molecular Pathology Publications 2004 - 2014**

Journal	Impact Factor	Title	Authors	Identifiers
Cancer Cell. 2013	27.059	The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity.	Qi J, Tripathi M, Mishra R, Sahgal N, Fazli L, Ettinger S, Placzek WJ, Claps G, Chung LW, Bowtell D, Gleave M, Bhowmick N, Ronai ZA.	PMID:23518348
Nat Med. 2010	22.462	Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance.	Tanaka H, Kono E, Tran CP, Miyazaki H, Yamashiro J, Shimomura T, Fazli L, Wada R, Huang J, Vessella RL, An J, Horvath S, Gleave M, Rettig MB, Wainberg ZA, Reiter RE.	PMID:21057494
Cancer Cell. 2004	18.122	Regulation of tumor angiogenesis by integrin-linked kinase (ILK).	Tan C, Cruet-Hennequart S, Troussard A, Fazli L, Costello P, Sutton K, Wheeler J, Gleave M, Sanghera J, Dedhar S.	PMID:14749128
J Natl Cancer Inst. 2005	15.171	A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer.	Chi KN, Eisenhauer E, Fazli L, Jones EC, Goldenberg SL, Powers J, Tu D, Gleave ME.	PMID:16145049
J Natl Cancer Inst. 2013	14.336	Targeting Amino Acid Transport in Metastatic Castration Resistant Prostate Cancer: Effects on Cell Cycle, Cell Growth, and Tumor Development	Wang Q ¹ , Tiffen J, Bailey CG, Lehman ML, Ritchie W, Fazli L, Metierre C, Feng YJ, Li E, Gleave M, Buchanan G, Nelson CC, Rasko JE, Holst J.	PMID: 24052624
Eur Urol. 2014	10.476	Suppression of Heat Shock Protein 27 Using OGX-427 Induces Endoplasmic Reticulum Stress and Potentiates Heat Shock Protein 90 Inhibitors to Delay Castrate-resistant Prostate Cancer.	Lamoureux F, Thomas C, Yin MJ, Fazli L, Zoubeidi A, Gleave ME.	PMID: 24411988
Proc Natl Acad Sci U S A. 2014	9.737	Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer.	ang S, Kollipara RK, Srivastava N, Li R, Ravindranathan P, Hernandez E, Freeman E, Humphries CG, Kapur P, Lotan Y, Fazli L, Gleave ME, Plymate SR, Raj GV, Hsieh JT, Kittler R.	PMID:24591637
Proc Natl Acad Sci U S A. 2007	9.6	Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development.	Gironella M, Seux M, Xie MJ, Cano C, Tomasini R, Gommeaux J, Garcia S, Nowak J, Yeung ML, Jeang KT, Chaix A, Fazli L, Motoo Y, Wang Q, Rocchi P, Russo A, Gleave M, Dagorn JC, Iovanna JL, Carrier A, PÁ@busque MJ, Dusetti NJ.	PMID:17911264
EMBO J. 2011	9.205	The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis.	Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L, Warren A, Scott H, Madhu B, Sharma N, Bon H, Zecchini V, Smith DM, Denicola GM, Mathews N, Osborne M, Hadfield J, Macarthur S, Adryan B, Lyons SK, Brindle KM, Griffiths J, et al.	PMID:21602788
Cancer Res. 2014	8.65	High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development.	Lin D, Wyatt AW, Xue H, Wang Y, Dong X, Haegert A, Wu R, Brahmabhatt S, Mo F, Jong L, Bell RH, Anderson S, Hurtado-Coll A, Fazli L, Sharma M, Beltran H, Rubin M, Cox M, Gout PW, Morris J, Goldenberg L, Volik SV, Gleave ME, Collins CC, Wang Y.	PMID: 24356420
Cancer Res. 2010	8.234	Hsp27 promotes insulin-like growth factor-1 survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD.	Zoubeidi A, Zardan A, Wiedmann RM, Locke J, Beraldi E, Fazli L, Gleave ME.	PMID:20197463
J Control Release. 2013	8.078	Fusidic acid and rifampicin co-loaded PLGA nanofibers for the prevention of orthopedic implant associated infections.	Gilchrist SE, Lange D, Letchford K, Bach H, Fazli L, Burt HM.	PMID:23639451
Cancer Res. 2013	7.86	Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer.	Shiota M, Bishop JL, Nip KM, Zardan A, Takeuchi A, Cordonnier T, Beraldi E, Bazov J, Fazli L, Chi K, Gleave M, Zoubeidi A.	PMID:23492367
Cancer Res. 2011	7.856	Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer.	Lamoureux F, Thomas C, Yin MJ, Kuruma H, Beraldi E, Fazli L, Zoubeidi A, Gleave ME.	PMID:21737488
Clin Cancer Res. 2014	7.837	miR-409-3p/-5p promotes tumorigenesis, epithelial to mesenchymal transition and bone metastasis of human prostate cancer.	Josson S, Gururajan M, Hu P, Shao C, Chu CY, Zhou HE, Liu C, Lao K, Lu CL, Lu YT, Lichterman J, Nandana S, Li Q, Rogatko A, Berel D, Posadas EM, Fazli L, Sareen D, Chung LW.	PMID: 24963047
Clin Cancer Res. 2013	7.837	The Mechanism of DAB2IP in Chemoresistance of Prostate Cancer Cells.	Wu K, Xie D, Zou Y, Zhang T, Pong RC, Xiao G, Fazli L, Gleave M, He D, Boothman DA, Hsieh JT.	PMID:23838317
Clin Cancer Res. 2012	7.742	A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancer.	Chi KN, Gleave ME, Fazli L, Goldenberg SL, So A, Kollmannsberger C, Murray N, Tinker A, Pollak M.	PMID:22553344
Clin Cancer Res. 2011	7.742	A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis.	Lamoureux F, Thomas C, Yin MJ, Kuruma H, Fazli L, Gleave ME, Zoubeidi A.	PMID:21349995
Cancer Res. 2004	7.69	Increased insulin-like growth factor 1 receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model.	Krueckl SL, Sikes RA, Edlund NM, Bell RH, Hurtado-Coll A, Fazli L, Gleave ME, Cox ME.	PMID:15574769
Cancer Res. 2004	7.69	Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer.	Rocchi P, So A, Kojima S, Signaevsky M, Beraldi E, Fazli L, Hurtado-Coll A, Yamanaka K, Gleave M.	PMID:15374973
Cancer Res. 2007	7.672	Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity.	Zoubeidi A, Zardan A, Beraldi E, Fazli L, Sowery R, Rennie P, Nelson C, Gleave M.	PMID:17974989
Cancer Res. 2007	7.672	Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer.	Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman IM, True LD, Knudsen B, Hess DL, Nelson CC, Matsumoto AM, Bremner WJ, Gleave ME, Nelson PS.	PMID:17510436
Cancer Res. 2007	7.672	DJ-1 binds androgen receptor directly and mediates its activity in hormonally treated prostate cancer cells.	Tillman JE, Yuan J, Gu G, Fazli L, Ghosh R, Flynt AS, Gleave M, Rennie PS, Kasper S.	PMID:17510388
Cancer Res. 2005	7.616	Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.	Rocchi P, Beraldi E, Ettinger S, Fazli L, Vessella RL, Nelson C, Gleave M.	PMID:16322258

**Vancouver Prostate Centre
Molecular Pathology Publications 2004 - 2014**

Journal	Impact Factor	Title	Authors	Identifiers
Cancer Res. 2008	7.514	Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer.	Hadaschik BA, Zhang K, So AI, Fazli L, Jia W, Bell JC, Gleave ME, Rennie PS.	PMID:18559493
Cancer Res. 2008	7.514	ASAP1, a gene at 8q24, is associated with prostate cancer metastasis.	Lin D, Watahiki A, Bayani J, Zhang F, Liu L, Ling V, Sadar MD, English J, Fazli L, So A, Gout PW, Gleave M, Squire JA, Wang YZ.	PMID:18519696
Oncogene. 2013	7.414	The role of DAB2IP in androgen receptor activation during prostate cancer progression.	Wu K, Liu J, Tseng SF, Gore C, Ning Z, Sharifi N, Fazli L, Gleave M, Kapur P, Xiao G, Sun X, Oz OK, Min W, Alexandrakis G, Yang CR, Hsieh CL, Wu HC, He D, Xie D, Hsieh JT.	PMID:23604126
Oncogene. 2010	7.414	Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E.	Andrieu C, Taieb D, Baylot V, Ettinger S, Soubeyran P, De-Thonel A, Nelson C, Garrido C, So A, Fazli L, Bladou F, Gleave M, Iovanna JL, Rocchi P.	PMID:20101233
Biomaterials. 2012	7.404	Tissue uptake of docetaxel loaded hydrophobically derivatized hyperbranched polyglycerols and their effects on the morphology of the bladder urothelium.	Mugabe C, Raven PA, Fazli L, Baker JH, Jackson JK, Liggins RT, So AI, Gleave ME, Minchinton AJ, Brooks DE, Burt HM.	PMID:22014457
Clin Cancer Res. 2010	7.338	Expression of receptors for luteinizing hormone-releasing hormone (LH-RH) in prostate cancers following therapy with LH-RH agonists.	Liu SV, Schally AV, Hawes D, Xiong S, Fazli L, Gleave M, Cai J, Groshen S, Brands F, Engel J, Pinski J.	PMID:20670943
Mol Ther. 2013	6.825	Targeting and killing of metastatic cells in the transgenic adenocarcinoma of mouse prostate model with vesicular stomatitis virus.	Moussavi M, Tearle H, Fazli L, Bell JC, Jia W, Rennie PS.	PMID:23337981
Mol Ther. 2012	6.825	Targeting TCTP as a New Therapeutic Strategy in Castration-resistant Prostate Cancer.	Baylot V, Katsogiannou M, Andrieu C, Taieb D, Acunzo J, Giusiano S, Fazli L, Gleave M, Garrido C, Rocchi P.	PMID:22893039
Clin Cancer Res. 2009	6.747	In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors.	Snoek R, Cheng H, Margiotti K, Wafa LA, Wong CA, Wong EC, Fazli L, Nelson CC, Gleave ME, Rennie PS.	PMID:19118031
Clin Cancer Res. 2008	6.488	Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer.	So AI, Levitt RJ, Eigl B, Fazli L, Muramaki M, Leung S, Cheang MC, Nielsen TO, Gleave M, Pollak M.	PMID:18980989
Clin Cancer Res. 2008	6.488	GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer.	Narita S, So A, Ettinger S, Hayashi N, Muramaki M, Fazli L, Kim Y, Gleave ME.	PMID:18794086
Clin Cancer Res. 2008	6.488	Intravesical chemotherapy of high-grade bladder cancer with HTI-286, a synthetic analogue of the marine sponge product hemiasterlin.	Hadaschik BA, Adomat H, Fazli L, Fradet Y, Andersen RJ, Gleave ME, So AI.	PMID:18316576
J Clin Endocrinol Metab. 2013	6.43	Expression and function of the progesterone receptor in human prostate stroma provide novel insights to cell proliferation control.	Yu Y, Liu L, Xie N, Xue H, Fazli L, Buttyan R, Wang Y, Gleave M, Dong X.	PMID:23666965
J Pathol. 2012	6.318	From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer.	Lapuk AV, Wu C, Wyatt AW, McPherson A, McConeghy BJ, Brahmabhatt S, Mo F, Zoubeidi A, Anderson S, Bell RH, Haegert A, Shukin R, Wang Y, Fazli L, Hurtado-Coll A, Jones EC, Hach F, Hormozdiari F, Hajirasouliha I, Boutros PC, Bristow RG, Zhao Y, et al.	PMID:22553170
J Pathol. 2012	6.318	Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer.	Wu C, Wyatt AW, Lapuk AV, McPherson A, McConeghy BJ, Bell RH, Anderson S, Haegert A, Brahmabhatt S, Shukin R, Mo F, Li E, Fazli L, Hurtado-Coll A, Jones EC, Butterfield YS, Hach F, Hormozdiari F, Hajirasouliha I, Boutros PC, Bristow RG, Jones SJ, et al.	PMID:22294438
Int J Cancer. 2013	6.198	TAK-441, a novel investigational smoothed antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling.	Ibuki N, Ghaffari M, Pandey M, lu I, Fazli L, Kashiwagi M, Tojo H, Nakanishi O, Gleave ME, Cox ME.	PMID:23564295
J Clin Endocrinol Metab. 2012	5.967	Differential expression of the androgen-conjugating UGT2B15 and UGT2B17 enzymes in prostate tumor cells during cancer progression.	PÃ¶quet S, Fazli L, Grosse L, Verreault M, TÃ¢tu B, Rennie PS, BÃ¶langer A, Barbier O.	PMID:22170718
Am J Pathol. 2005	5.796	Regulation of hepatocyte activator inhibitor-1 expression by androgen and oncogenic transformation in the prostate.	Knudsen BS, Lucas JM, Fazli L, Hawley S, Falcon S, Coleman IM, Martin DB, Xu C, True LD, Gleave ME, Nelson PS, Ayala GE.	PMID:15972969
Mol Cancer Ther. 2013	5.599	Synergistic targeting of PI3K/AKT-pathway and androgen-receptor axis significantly delays castration-resistant prostate cancer progression in vivo.	Thomas C, Lamoureux F, Crafter C, Davies BR, Beraldi E, Fazli L, Kim S, Thaper D, Gleave ME, Zoubeidi A.	PMID:23966621
Pharmacol Ther. 2002	5.571	Integrin-linked kinase, a promising cancer therapeutic target: biochemical and biological properties.	Yoganathan N, Yee A, Zhang Z, Leung D, Yan J, Fazli L, Kojic DL, Costello PC, Jabali M, Dedhar S, Sanghera J.	PMID:12191615
J Biol Chem. 2008	5.52	The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells.	Xie Y, Xu K, Linn DE, Yang X, Guo Z, Shimelis H, Nakanishi T, Ross DD, Chen H, Fazli L, Gleave ME, Qiu Y.	PMID:18056989
Int J Cancer. 2012	5.444	Carbidopa abrogates L-dopa decarboxylase coactivation of the androgen receptor and delays prostate tumor progression.	Wafa LA, Cheng H, Plaa N, Ghaidi F, Fukumoto T, Fazli L, Gleave ME, Cox ME, Rennie PS.	PMID:21780103
Endocr Relat Cancer. 2013	5.261	IGF2 increases de novo steroidogenesis in prostate cancer cells.	Lubik AA, Gunter JH, Hollier BG, Ettinger S, Fazli L, Stylianou N, Hendy SC, Adomat HH, Gleave ME, Pollak M, Herington A, Nelson CC.	PMID:23319492
Mol Cancer Ther. 2012	5.226	Cotargeting stress-activated Hsp27 and autophagy as a combinatorial strategy to amplify endoplasmic reticular stress in prostate cancer.	Kumano M, Furukawa J, Shiota M, Zardan A, Zhang F, Beraldi E, Wiedmann RM, Fazli L, Zoubeidi A, Gleave ME.	PMID:22675041
Mol Cancer Ther. 2012	5.226	Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target.	Collins CC, Volik SV, Lapuk AV, Wang Y, Gout PW, Wu C, Xue H, Cheng H, Haegert A, Bell RH, Brahmabhatt S, Anderson S, Fazli L, Hurtado-Coll A, Rubin MA, Demichelis F, Beltran H, Hirst M, Marra M, Maher CA, Chinnaiyan AM, Gleave M, et al.	PMID:22252602
Mol Cancer Ther. 2011	5.226	Transcription factor Stat5 knockdown enhances androgen receptor degradation and delays castration-resistant prostate cancer progression in vivo.	Thomas C, Zoubeidi A, Kuruma H, Fazli L, Lamoureux F, Beraldi E, Monia BP, MacLeod AR, ThÃ¼roff JW, Gleave ME.	PMID:21216933

**Vancouver Prostate Centre
Molecular Pathology Publications 2004 - 2014**

Journal	Impact Factor	Title	Authors	Identifiers
Mol Cancer Ther. 2005	5.171	Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo.	So A, Sinnemann S, Huntsman D, Fazli L, Gleave M.	PMID:16373699
Mol Cancer Ther. 2005	5.171	A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells.	Yamanaka K, Rocchi P, Miyake H, Fazli L, Vessella B, Zangemeister-Wittke U, Gleave ME.	PMID:16275990
Mol Cancer Ther. 2009	4.953	Intravesical combination treatment with antisense oligonucleotides targeting heat shock protein-27 and HTI-286 as a novel strategy for high-grade bladder cancer.	Matsui Y, Hadaschik BA, Fazli L, Andersen RJ, Gleave ME, So AI.	PMID:19625496
Int J Cancer. 2010	4.926	Down-regulation of type I interferon receptor sensitizes bladder cancer cells to vesicular stomatitis virus-induced cell death.	Zhang KX, Matsui Y, Hadaschik BA, Lee C, Jia W, Bell JC, Fazli L, So AI, Rennie PS.	PMID:19957332
Mol Endocrinol. 2010	4.889	TAF1 differentially enhances androgen receptor transcriptional activity via its N-terminal kinase and ubiquitin-activating and -conjugating domains.	Tavassoli P, Wafa LA, Cheng H, Zoubeidi A, Fazli L, Gleave M, Snoek R, Rennie PS.	PMID:20181722
Mol Cancer Ther. 2004	4.813	Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo.	July LV, Beraldi E, So A, Fazli L, Evans K, English JC, Gleave ME.	PMID:15026542
Oncotarget. 2014	4.784	GATA2 as a potential metastasis-driving gene in prostate cancer.	Chiang YT, Wang K, Fazli L, Qi RZ, Gleave ME, Collins CC, Gout PW, Wang Y.	PMID: 24448395
Cancer. 2010	4.771	Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer.	Garzotto M, Higano CS, O'Brien C, Rademacher BL, Janeba N, Fazli L, Lange PH, Lieberman S, Beer TM.	PMID:20143429
Int J Cancer. 2006	4.693	Cyclin G-associated kinase: a novel androgen receptor-interacting transcriptional coactivator that is overexpressed in hormone refractory prostate cancer.	Ray MR, Wafa LA, Cheng H, Snoek R, Fazli L, Gleave M, Rennie PS.	PMID:16161052
Med Image Comput Assist Interv, 2013	4.662	Separation of benign and malignant glands in prostatic adenocarcinoma.	Rashid S, Fazli L, Boag A, Siemens R, Abolmaesumi P, Salcudean SE.	PMID: 24505794
Mol Endocrinol. 2012	4.544	Slug, a unique androgen-regulated transcription factor, coordinates androgen receptor to facilitate castration resistance in prostate cancer.	Wu K, Gore C, Yang L, Fazli L, Gleave M, Pong RC, Xiao G, Zhang L, Yun EJ, Tseng SF, Kapur P, He D, Hsieh JT.	PMID:22745193
PLoS One. 2012	4.4	Identification of CD166 as a surface marker for enriching prostate stem/progenitor and cancer initiating cells.	Jiao J, Hindoyan A, Wang S, Tran LM, Goldstein AS, Lawson D, Chen D, Li Y, Guo C, Zhang B, Fazli L, Gleave M, Witte ON, Garraway IP, Wu H.	PMID:22880034
Clin Exp Metastasis. 2014	4.29	A humanized tissue-engineered in vivo model to dissect interactions between human prostate cancer cells and human bone.	Hesami P, Holzapfel BM, Taubenberger A, Roudier M, Fazli L, Sieh S, Thibaudeau L, Gregory LS, Huttmacher DW, Clements JA.	PMID: 24510218.
PLoS One. 2014	4.24	Prostate stromal cells express the progesterone receptor to control cancer cell mobility.	Yu Y, Lee JS, Xie N, Li E, Hurtado-Coll A, Fazli L, Cox M, Plymate S, Gleave M, Dong X.	PMID: 24664419
Cancer Lett. 2012	4.238	Histone H2A.Z prepares the prostate specific antigen (PSA) gene for androgen receptor-mediated transcription and is upregulated in a model of prostate cancer progression.	Dryhurst D, McMullen B, Fazli L, Rennie PS, Ausi ³ J.	PMID:22055461
Cancer Gene Ther. 2006	4.187	Targeting and killing of prostate cancer cells using lentiviral constructs containing a sequence recognized by translation factor eIF4E and a prostate-specific promoter.	Yu D, Scott C, Jia WW, De Benedetti A, Williams BJ, Fazli L, Wen Y, Gleave M, Nelson C, Rennie PS.	PMID:16052226
Cancer Epidemiol Biomarkers Prev. 2013	4.12	Protein expression of PTEN, insulin-like growth factor I receptor (IGF1R), and lethal prostate cancer: a prospective study.	Zu K, Martin NE, Fiorentino M, Flavin R, Lis RT, Sinnott JA, Finn SP, Penney KL, Ma J, Fazli L, Gleave ME, Bismar TA, Stampfer MJ, Pollak MN, Loda M, Mucci LA, Giovannucci EL.	PMID:23983239
PLoS One. 2013	4.09	Ultrasound-guided intramural inoculation of orthotopic bladder cancer xenografts: a novel high-precision approach.	JÄrger W, Moskalev I, Janssen C, Hayashi T, Awrey S, Gust KM, So AI, Zhang K, Fazli L, Li E, ThÄ¼rroff JW, Lange D, Black PC.	PMID:23555699
PLoS One. 2013	4.09	BIRC6 protein, an inhibitor of apoptosis: role in survival of human prostate cancer cells.	Low CG, Luk IS, Lin D, Fazli L, Yang K, Xu Y, Gleave M, Gout PW, Wang Y.	PMID:23409057
J Urol. 2006	3.956	Rh2 synergistically enhances paclitaxel or mitoxantrone in prostate cancer models.	Xie X, Eberding A, Madera C, Fazli L, Jia W, Goldenberg L, Gleave M, Guns ES.	PMID:16600800
J Urol. 2008	3.952	Investigation of a novel degradable ureteral stent in a porcine model.	Hadaschik BA, Paterson RF, Fazli L, Clinkscales KW, Shalaby SW, Chew BH.	PMID:18639278
Prostate. 2013	3.843	Expression and role of the angiotensin II AT2 receptor in human prostate tissue: in search of a new therapeutic option for prostate cancer.	Guimond MO, Battista MC, Nikjoutavabi F, Carmel M, Barres V, Doueik AA, Fazli L, Gleave M, Sabbagh R, Gallo-Pavet N.	PMID:23389987
J Urol. 2011	3.746	The potential impact of reproducibility of Gleason grading in men with early stage prostate cancer managed by active surveillance: a multi-institutional study.	McKenney JK, Simko J, Bonham M, True LD, Troyer D, Hawley S, Newcomb LF, Fazli L, Kunju LP, Nicolas MM, Vakar-Lopez F, Zhang X, Carroll PR, Brooks JD; Canary/Early Detection Research Network Prostate Active Surveillance Study Investigators.	PMID:21679996
Prostate. 2006	3.724	Relaxin becomes upregulated during prostate cancer progression to androgen independence and is negatively regulated by androgens.	Thompson VC, Morris TG, Cochrane DR, Cavanagh J, Wafa LA, Hamilton T, Wang S, Fazli L, Gleave ME, Nelson CC.	PMID:16998820
Prostate. 2006	3.724	Clusterin is not essential for androgen-regulated involution and regeneration of the normal mouse prostate.	Fink D, Fazli L, Aronow B, Gleave ME, Ong CJ.	PMID:16865725
Prostate. 2006	3.724	Differential regulation of IGFBP-3 by the androgen receptor in the lineage-related androgen-dependent LNCaP and androgen-independent C4-2 prostate cancer models.	Kojima S, Mulholland DJ, Ettinger S, Fazli L, Nelson CC, Gleave ME.	PMID:16541420
Prostate. 2006	3.724	Loss of PTEN is associated with progression to androgen independence.	Bertram J, Peacock JW, Fazli L, Mui AL, Chung SW, Cox ME, Monia B, Gleave ME, Ong CJ.	PMID:16496415
Prostate. 2007	3.674	Regulation of global gene expression in the bone marrow microenvironment by androgen: androgen ablation increases insulin-like growth factor binding protein-5 expression.	Xu C, Graf LF, Fazli L, Coleman IM, Mauldin DE, Li D, Nelson PS, Gleave M, Plymate SR, Cox ME, Torok-Storb BJ, Knudsen BS.	PMID:17823924
Prostate. 2007	3.674	Increased expression and differential phosphorylation of stathmin may promote prostate cancer progression.	Ghosh R, Gu G, Tillman E, Yuan J, Wang Y, Fazli L, Rennie PS, Kasper S.	PMID:17455228

**Vancouver Prostate Centre
Molecular Pathology Publications 2004 - 2014**

Journal	Impact Factor	Title	Authors	Identifiers
Prostate. 2012	3.485	TP53INP1 as new therapeutic target in castration-resistant prostate cancer.	Giusiano S, Baylot V, Andrieu C, Fazli L, Gleave M, Iovanna JL, Taranger-Charpin C, Garcia S, Rocchi P.	PMID:22213058
Prostate. 2012	3.485	Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.	Thomas C, Wafa LA, Lamoureux F, Cheng H, Fazli L, Gleave ME, Rennie PS.	PMID:22072572
Adv Anat Pathol. 2013	3.412	A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray.	Hawley S, Fazli L, McKenney JK, Simko J, Troyer D, Nicolas M, Newcomb LF, Cowan JE, Crouch L, Ferrari M, Hernandez J, Hurtado-Coll A, Kuchinsky K, Liew J, Mendez-Meza R, Smith E, Tenggara I, Zhang X, Carroll PR, Chan JM, Gleave M, Lance R, et al.	PMID:23232570
Transl Oncol. 2012	3.393	The 16p13.3 (PDPK1) Genomic Gain in Prostate Cancer: A Potential Role in Disease Progression.	Choucair KA, GuÃ©rard KP, Ejdelman J, Chevalier S, Yoshimoto M, Scariata E, Fazli L, Sircar K, Squire JA, Brimo F, Cunha IW, Aprikian A, Gleave M, Lapointe J.	PMID:23401739
Prostate. 2010	3.377	Relaxin drives Wnt signaling through upregulation of PCDHY in prostate cancer.	Thompson VC, Hurtado-Coll A, Turbin D, Fazli L, Lehman ML, Gleave ME, Nelson CC.	PMID:20503398
Prostate. 2010	3.377	Inhibition of DHCR24/seladin-1 impairs cellular homeostasis in prostate cancer.	Battista MC, Guimond MO, Roberge C, Doueik AA, Fazli L, Gleave M, Sabbagh R, Gallo-Payet N.	PMID:20166102
Prostate. 2010	3.377	Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistance.	Locke JA, Guns ES, Lehman ML, Ettinger S, Zoubeidi A, Lubik A, Margiotti K, Fazli L, Adomat H, Wasan KM, Gleave ME, Nelson CC.	PMID:19790237
Cancer Gene Ther. 2009	3.126	Lentiviruses with trastuzumab bound to their envelopes can target and kill prostate cancer cells.	Zhang KX, Moussavi M, Kim C, Chow E, Chen IS, Fazli L, Jia W, Rennie PS.	PMID:19373278
BMC Cancer. 2008	3.087	Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer.	FitzGerald LM, Agalliu I, Johnson K, Miller MA, Kwon EM, Hurtado-Coll A, Fazli L, Rajput AB, Gleave ME, Cox ME, Ostrander EA, Stanford JL, Huntsman DG.	PMID:18694509
Prostate. 2009	3.081	A novel communication role for CYP17A1 in the progression of castration-resistant prostate cancer.	Locke JA, Fazli L, Adomat H, Smyl J, Weins K, Lubik AA, Hales DB, Nelson CC, Gleave ME, Tomlinson Guns ES.	PMID:19267349
Prostate. 2009	3.081	Insulin receptor expression by human prostate cancers.	Cox ME, Gleave ME, Zakikhani M, Bell RH, Piura E, Vickers E, Cunningham M, Larsson O, Fazli L, Pollak M.	PMID:18785179
Prostate. 2008	3.069	Effects of Eg5 knockdown on human prostate cancer xenograft growth and chemosensitivity.	Hayashi N, Koller E, Fazli L, Gleave ME.	PMID:18512732
Hum Pathol. 2007	3.034	Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors.	Wafa LA, Palmer J, Fazli L, Hurtado-Coll A, Bell RH, Nelson CC, Gleave ME, Cox ME, Rennie PS.	PMID:16997353
Cancer Gene Ther. 2012	2.802	Fibroblast growth factor and ornithine decarboxylase 5'UTRs enable preferential expression in human prostate cancer cells and in prostate tumors of PTEN(-/-) transgenic mice.	Moussavi M, Moshgabadi N, Fazli L, Leblanc E, Zhang K, Jia W, Rennie PS.	PMID:21921943
BJU Int. 2007	2.751	A validated mouse model for orthotopic bladder cancer using transurethral tumour inoculation and bioluminescence imaging.	Hadaschik BA, Black PC, Sea JC, Metwalli AR, Fazli L, Dinney CP, Gleave ME, So AI.	PMID:17850390
BJU Int. 2007	2.751	Non-invasive evaluation of tumour hypoxia in the Shionogi tumour model for prostate cancer with 18F-EF5 and positron emission tomography.	Yapp DT, Woo J, Kartono A, Sy J, Oliver T, Skov KA, Koch CJ, Adomat H, Dragowska WH, Fazli L, Ruth T, Adam MJ, Green D, Gleave M.	PMID:17309552
BJU Int. 2008	2.704	Intravesically administered antisense oligonucleotides targeting heat-shock protein-27 inhibit the growth of non-muscle-invasive bladder cancer.	Hadaschik BA, Jackson J, Fazli L, Zoubeidi A, Burt HM, Gleave ME, So AI.	PMID:18384625
BJU Int. 2008	2.704	Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy.	Sowery RD, Hadaschik BA, So AI, Zoubeidi A, Fazli L, Hurtado-Coll A, Gleave ME.	PMID:18336596
Cancer Chemother Pharmacol. 2009	2.654	Pre-clinical evaluation of Rh2 in PC-3 human xenograft model for prostate cancer in vivo: formulation, pharmacokinetics, biodistribution and efficacy.	Musende AG, Eberding A, Wood C, Adomat H, Fazli L, Hurtado-Coll A, Jia W, Bally MB, Guns ET.	PMID:19301006
BJU Int. 2006	2.635	Small interference RNA targeting heat-shock protein 27 inhibits the growth of prostatic cell lines and induces apoptosis via caspase-3 activation in vitro.	Rocchi P, Juggal P, So A, Sinneman S, Ettinger S, Fazli L, Nelson C, Gleave M.	PMID:16879439
BJU Int. 2006	2.635	Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes.	Yamanaka K, Rocchi P, Miyake H, Fazli L, So A, Zangemeister-Wittke U, Gleave ME.	PMID:16686729
Cancer Chemother Pharmacol. 2007	2.568	Assessing the therapeutic and toxicological effects of cesium chloride following administration to nude mice bearing PC-3 or LNCaP prostate cancer xenografts.	Low JC, Wasan KM, Fazli L, Eberding A, Adomat H, Guns ES.	PMID:17294190
J Clin Pathol. 2007	2.426	Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers.	Rajput AB, Miller MA, De Luca A, Boyd N, Leung S, Hurtado-Coll A, Fazli L, Jones EC, Palmer JB, Gleave ME, Cox ME, Huntsman DG.	PMID:17259299
Anticancer Drugs. 2012	2.407	A novel oral dosage formulation of the ginsenoside aglycone protopanaxadiol exhibits therapeutic activity against a hormone-insensitive model of prostate cancer.	Musende AG, Eberding A, Wood CA, Adomat H, Fazli L, Hurtado-Coll A, Jia W, Bally MB, Tomlinson Guns ES.	PMID:22481061